NAUT | Nautilus Biotechnology, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.9601 - 2.1100
52 Week Range	1.6100 - 3.12
Beta	1.25
Implied Volatility	216.04%
IV Rank	38.56%
Day's Volume	91,397
Average Volume	140,780
Shares Outstanding	125,564,000
Market Cap	256,150,560
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-08-07

Valuation
Profitability
Growth
Health
P/E Ratio	-3.64
Forward P/E Ratio	-4.74
EPS	-0.56
1YR Price Target	9.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	161
Country	USA
Website	NAUT

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.

NAUT's peers: BCAB, CCCC, KYMR, FHTX, RVMD, IPSC, PMVP, CRBU, FIXX, DTIL, BEAM, MNOV, ELYM, MOLN, CSBR, CYT, ANEB, RZLT, HCWB, MAIA

*Chart delayed

Analyzing fundamentals for NAUT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see NAUT Fundamentals page.

Watching at NAUT technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on NAUT Technicals page.